LU91867I2 - Fingolimod et ses dérivés pharmaceutiquement acceptables (GILENYA®) - Google Patents

Fingolimod et ses dérivés pharmaceutiquement acceptables (GILENYA®)

Info

Publication number: LU91867I2
Authority: LU; Luxembourg
Prior art keywords: gilenya; fingolimod; pharmaceutically acceptable; acceptable derivatives; pharmaceutical composition
Prior art date: 2003-04-08

Application number

LU91867C

Other languages

English (en)

Other versions

LU91867I9 (fr

Original Assignee

Novartis Ag

Mitsubishi Tanabe Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-08

Filing date

2011-09-08

Publication date

2011-11-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91867(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-09-08 Application filed by Novartis Ag, Mitsubishi Tanabe Pharma Corp filed Critical Novartis Ag

2011-11-08 Publication of LU91867I2 publication Critical patent/LU91867I2/fr

2019-01-03 Publication of LU91867I9 publication Critical patent/LU91867I9/fr

Links

KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 title 2
229960000556 fingolimod Drugs 0.000 title 2
102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 1
108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000018 receptor agonist Substances 0.000 abstract 1
229940044601 receptor agonist Drugs 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1
150000005846 sugar alcohols Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Surgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

LU91867C 2003-04-08 2011-09-08 Fingolimod et ses dérivés pharmaceutiquement acceptables (GILENYA®) LU91867I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46121503P	2003-04-08	2003-04-08
PCT/EP2004/003656 WO2004089341A1 (fr)	2003-04-08	2004-04-06	Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Publications (2)

Publication Number	Publication Date
LU91867I2 true LU91867I2 (fr)	2011-11-08
LU91867I9 LU91867I9 (fr)	2019-01-03

Family

ID=32326722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU91867C LU91867I2 (fr)	2003-04-08	2011-09-08	Fingolimod et ses dérivés pharmaceutiquement acceptables (GILENYA®)

Country Status (41)

Country	Link
US (11)	US20060275357A1 (fr)
EP (5)	EP2316431B1 (fr)
JP (3)	JP5495467B2 (fr)
KR (3)	KR20050121712A (fr)
CN (2)	CN101797241B (fr)
AR (3)	AR043987A1 (fr)
AT (3)	AT501681B1 (fr)
AU (1)	AU2004228929B2 (fr)
BE (2)	BE1015972A5 (fr)
BR (1)	BRPI0409250B8 (fr)
CA (2)	CA2521325C (fr)
CL (2)	CL2004000745A1 (fr)
CY (3)	CY1110260T1 (fr)
DE (4)	DE122011100047I1 (fr)
DK (2)	DK1613288T3 (fr)
EC (1)	ECSP056090A (fr)
ES (3)	ES2320767T3 (fr)
FR (2)	FR2854073B1 (fr)
GB (1)	GB2400318B (fr)
GR (1)	GR1005052B (fr)
HR (3)	HRP20100601B1 (fr)
HU (2)	HUE028247T2 (fr)
IL (3)	IL170888A (fr)
IS (2)	IS2682B (fr)
IT (1)	ITMI20040682A1 (fr)
LU (1)	LU91867I2 (fr)
MA (1)	MA27729A1 (fr)
MX (1)	MXPA05010860A (fr)
MY (1)	MY141249A (fr)
NO (4)	NO329332B1 (fr)
NZ (3)	NZ586280A (fr)
PE (5)	PE20130200A1 (fr)
PL (2)	PL1613288T3 (fr)
PT (1)	PT1613288E (fr)
RU (5)	RU2358716C2 (fr)
SG (1)	SG175449A1 (fr)
SI (2)	SI2316431T1 (fr)
TN (1)	TNSN05256A1 (fr)
TW (1)	TWI332847B (fr)
WO (1)	WO2004089341A1 (fr)
ZA (1)	ZA200507394B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL1773307T3 (pl) *	2004-07-30	2015-03-31	Novartis Ag	Preparaty 2-amino-1,3-propanodioli i ich analogów
CN1891212B (zh) *	2005-07-07	2010-10-13	马启明	一种口服制剂及其制备方法
ES2529724T3 (es) *	2005-09-09	2015-02-25	Novartis Ag	Tratamiento de enfermedades autoinmunes
MY171061A (en)	2005-11-09	2019-09-24	Onyx Therapeutics Inc	Compounds for enzyme inhibition
TWI389683B (zh) *	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CA2657213C (fr)	2006-06-19	2017-01-03	Proteolix, Inc.	Peptides epoxycetones pour l'inhibition de proteasomes
GB0612721D0 (en)	2006-06-27	2006-08-09	Novartis Ag	Organic compounds
EP1905434A1 (fr) *	2006-09-26	2008-04-02	Novartis AG	Compositions organiques comprenant d'un agoniste de S1P recepteur et leur utilisation therapeutique
EP1923058A1 (fr) *	2006-09-26	2008-05-21	Novartis AG	Composition pharmaceutique enrobée comprenant un agoniste ou un modulateur de S1P
EP1923054A1 (fr) *	2006-09-26	2008-05-21	Novartis AG	Composition pharmaceutique à désintégration rapide comprenant un agoniste ou modulateur de S1P
AU2011235934A1 (en) *	2006-09-26	2011-11-03	Novartis Ag	Pharmaceutical compositions comprising an S1P modulator
HUE046441T2 (hu) *	2006-09-26	2020-02-28	Novartis Ag	S1P modulátort tartalmazó gyógyászati készítmények
EP1923055A1 (fr) *	2006-09-26	2008-05-21	Novartis AG	Composition pharmaceutique lyophilisée comprenant un agoniste ou modulateur de S1P
WO2008124210A1 (fr) *	2007-02-14	2008-10-16	Emory University	Procédés et compositions destinés à traiter ou prévenir une infection en utilisant des agents de séquestration des leucocytes
NZ597109A (en) *	2007-03-29	2013-01-25	Daiichi Sankyo Co Ltd	Tablet composition having favorable dissolution property useful as an anticoagulant
KR20170125413A (ko)	2007-10-04	2017-11-14	오닉스 세라퓨틱스, 인크.	결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
AU2012216630B2 (en) *	2007-10-12	2015-01-22	Novartis Ag	Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
EP3733161A1 (fr) *	2007-10-12	2020-11-04	Novartis AG	Compositions comprenant des modulateurs de récepteur de sphingosine 1 (s1p) phosphate
JP5534645B2 (ja) *	2008-01-11	2014-07-02	日医工株式会社	無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
TW200946105A (en)	2008-02-07	2009-11-16	Kyorin Seiyaku Kk	Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
PL2278960T5 (pl)	2008-03-17	2020-06-29	Actelion Pharmaceuticals Ltd.	Schemat dawkowania dla selektywnego agonisty receptora sip1
JP2011525189A (ja)	2008-06-20	2011-09-15	ノバルティスアーゲー	多発性硬化症を治療するための小児科の組成物
BRPI0914164B1 (pt) *	2008-06-20	2019-04-30	Merck Patent Gmbh	Comistura para produção de comprimidos de desintegração rápida em um processo de formação de comprimido direto, seus usos, e formulações de comprimido
WO2010025796A1 (fr) *	2008-09-04	2010-03-11	Cargill Incorporated	Compression de l'érythritol
EP3090737A1 (fr)	2008-10-21	2016-11-09	Onyx Therapeutics, Inc.	Thérapie de combinaison avec peptides d'époxycétones
JP2012508215A (ja)	2008-11-11	2012-04-05	ノバルティスアーゲー	有機化合物
AU2013100531B4 (en) *	2008-11-11	2013-11-28	Novartis Ag	Crystalline forms of fingolimod HCL
PT2356090T (pt) *	2008-11-11	2017-10-16	Novartis Ag	Formas cristalinas de fingolimod, hcl
SI2371830T1 (sl)	2008-12-17	2014-01-31	Daiichi Sankyo Company, Limited	Postopek za pridobivanje diaminskih derivatov
EP2383272A4 (fr)	2009-01-13	2012-07-25	Daiichi Sankyo Co Ltd	Inhibiteur d'un facteur actif de la coagulation sanguine
WO2010104078A1 (fr)	2009-03-10	2010-09-16	第一三共株式会社	Procédé de production d'un dérivé de diamine
WO2010104106A1 (fr)	2009-03-13	2010-09-16	第一三共株式会社	Procédé de production d'un dérivé diamine optiquement actif
TWI504598B (zh)	2009-03-20	2015-10-21	Onyx Therapeutics Inc	結晶性三肽環氧酮蛋白酶抑制劑
MY155256A (en) *	2009-06-18	2015-09-30	Daiichi Sankyo Co Ltd	Pharmaceutical composition having improved solubility
US9675566B2 (en)	2009-07-16	2017-06-13	Pathologica Llc	Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
US8853147B2 (en)	2009-11-13	2014-10-07	Onyx Therapeutics, Inc.	Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (fr)	2010-03-01	2015-08-12	Onyx Therapeutics, Inc.	Composés pour inhibition de l'immunoprotéasome
CN102791719B (zh)	2010-03-19	2015-07-29	第一三共株式会社	二胺衍生物的晶体及其制备方法
JP5390014B2 (ja)	2010-03-19	2014-01-15	第一三共株式会社	抗凝固剤の溶出改善方法
EA201291095A1 (ru) *	2010-04-22	2013-04-30	Рациофарм Гмбх	Способ получения пероральной лекарственной формы, содержащей финголимод
CA2804262C (fr)	2010-07-02	2016-04-05	Daiichi Sankyo Company, Limited	Procede pour la preparation de sel derive de diamine optiquement actif
WO2012070059A1 (fr)	2010-11-25	2012-05-31	Shilpa Medicare Limited	Polymorphes du fingolimode et leurs procédés
JP6111202B2 (ja)	2011-01-07	2017-04-05	ノバルティスアーゲー	免疫抑制製剤
NO2665471T3 (fr)	2011-01-19	2018-05-26
AR085749A1 (es)	2011-04-01	2013-10-23	Novartis Ag	Formulaciones
US9186333B2 (en) *	2011-08-01	2015-11-17	Teva Pharmaceutical Industries Ltd.	Process for preparing pharmaceutical compositions of fingolimod
ES2673182T3 (es)	2011-08-10	2018-06-20	Daiichi Sankyo Company, Limited	Composición farmacéutica que contiene un derivado de diamina
WO2013091704A1 (fr)	2011-12-22	2013-06-27	Synthon Bv	Composition pharmaceutique comprenant le fingolimod
RU2482842C1 (ru) *	2012-04-26	2013-05-27	Открытое акционерное общество "Новосибхимфарм"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) *	2012-06-13	2014-02-20	Открытое акционерное общество "Новосибхимфарм"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US20140105921A1 (en)	2012-07-09	2014-04-17	Onyx Therapeutics, Inc.	Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
RU2496486C1 (ru) *	2012-07-11	2013-10-27	Александр Васильевич Иващенко	Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
CN109432073A (zh)	2013-01-08	2019-03-08	帕萨罗杰卡有限公司	Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途
WO2014141298A2 (fr) *	2013-03-11	2014-09-18	Astron Research Limited	Composition pharmaceutique stable de fingolimod
WO2014175287A1 (fr) *	2013-04-26	2014-10-30	国立大学法人京都大学	Composition médicinale destinée à empêcher la formation et/ou l'expansion d'un anévrisme cérébral ou réduire un tel anévrisme
WO2013190151A1 (fr) *	2013-05-13	2013-12-27	Synthon B.V.	Composition pharmaceutique contenant du fingolimod
EP3027174B1 (fr)	2013-07-29	2019-07-24	Aizant Drug Research Solutions Private Limited	Compositions pharmaceutiques à base de fingolimod
RU2530626C1 (ru) *	2013-10-21	2014-10-10	Ооо "Валента-Интеллект"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (fr) *	2014-08-22	2016-02-25	Sunshine Lake Pharma Co., Ltd.	Composition solide de fingolimod et préparation associée
WO2016042493A1 (fr) *	2014-09-19	2016-03-24	Aizant Drug Research Pvt. Ltd	Compositions pharmaceutiques de fingolimod
US9925138B2 (en)	2015-01-20	2018-03-27	Handa Pharmaceuticals, Llc	Stable solid fingolimod dosage forms
EP3247341A4 (fr) *	2015-01-20	2018-12-19	Handa Pharmaceuticals, Llc	Forme galénique solide stable de fingolimod
WO2016135644A1 (fr)	2015-02-26	2016-09-01	Novartis Ag	Traitement de maladie auto-immune chez un patient recevant en outre un bêtabloquant
RU2577230C1 (ru) *	2015-04-09	2016-03-10	Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус"	Способ получения капсул финголимода гидрохлорида
US9690975B2 (en)	2015-05-28	2017-06-27	Axogen Corporation	Quantitative structural assay of a nerve graft
US11434200B2 (en)	2017-03-09	2022-09-06	Novartis Ag	Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3419607B1 (fr)	2017-03-29	2019-11-20	Deva Holding Anonim Sirketi	Formulations stables de fingolimod
GR1009654B (el)	2018-08-31	2019-11-18	Φαρματεν Α.Β.Ε.Ε.	Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de)	2018-10-10	2020-04-16	Harbins Ruhr Bioscience, Inc.	Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) *	2020-05-18	2024-06-20	東和薬品株式会社	フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
BR112022023937A2 (pt)	2020-05-29	2022-12-27	Myovant Sciences Gmbh	Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
US11298412B2 (en)	2020-07-16	2022-04-12	Harbins Ruhr Bioscience, Inc.	Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection
AU2022214268A1 (en) *	2021-01-28	2023-07-27	Priothera Limited	Methods of treatment with s1p receptor modulators
WO2022162409A1 (fr) *	2021-01-28	2022-08-04	Priothera Sas	Procédés de traitement avec des modulateurs des récepteurs de la s1p

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL7607683A (nl) *	1976-07-12	1978-01-16	Akzo Nv	Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) *	1977-05-05	1978-08-29	Chevron Research Company	1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en)	1983-10-25	1985-12-17	Phillips Petroleum Company	Metal working lubricant
US5112616A (en) *	1988-11-30	1992-05-12	Schering Corporation	Fast dissolving buccal tablet
JP2841857B2 (ja) *	1990-11-29	1998-12-24	田辺製薬株式会社	長期間安定な経口用医薬製剤
DE69321823T2 (de)	1992-10-21	1999-06-02	Taito Co., Ltd., Tokio/Tokyo	2-amino-1, 3- propandiolverbindung und immunosuppressium
EP0778263B1 (fr)	1994-08-22	2002-01-09	Welfide Corporation	Compose benzenique et son utilisation medicale
WO1997024112A1 (fr)	1995-12-28	1997-07-10	Yoshitomi Pharmaceutical Industries, Ltd.	Preparation a usage externe
JPH11209277A (ja) *	1998-01-19	1999-08-03	Yoshitomi Pharmaceut Ind Ltd	医薬組成物
US6476004B1 (en) *	1996-07-18	2002-11-05	Mitsubishi Pharma Corporation	Pharmaceutical composition
JP2002241272A (ja)	1996-07-18	2002-08-28	Mitsubishi Pharma Corp	医薬処方組成物
GB9624038D0 (en)	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
KR20000075745A (ko) *	1997-02-27	2000-12-26	가마후라 아키오	의약 조성물
ES2240868T3 (es)	1997-04-04	2005-10-16	Mitsubishi Pharma Corporation	Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
JPH1180026A (ja) *	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja)	1998-04-01	2004-07-21	花王株式会社	スフィンゴ糖脂質の製造法
JP4627356B2 (ja)	1999-06-30	2011-02-09	昭松森	ウイルス性心筋炎の予防または治療薬剤
WO2001003739A1 (fr) *	1999-07-12	2001-01-18	Ono Pharmaceutical Co., Ltd.	Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
CN1328387C (zh)	2000-07-13	2007-07-25	三共株式会社	氨基醇衍生物
EP1315735A4 (fr)	2000-08-31	2005-04-06	Merck & Co Inc	Derives de phosphates utilises en tant qu'agents immuno-regulateurs
US6953332B1 (en)	2000-11-28	2005-10-11	St. Jude Medical, Inc.	Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
CA2442178A1 (fr)	2001-03-26	2002-10-03	Novartis Ag	Derives de 2-amino-propanol
US7521192B2 (en)	2001-04-18	2009-04-21	Rigel Pharmaceuticals, Inc.	EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja)	2001-04-20	2002-10-31	Sankyo Co Ltd	ベンゾチオフェン誘導体
EP1424078A4 (fr)	2001-09-04	2009-03-25	Ono Pharmaceutical Co	Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate
CA2461212C (fr)	2001-09-27	2010-08-17	Kyorin Pharmaceutical Co., Ltd.	Derive de sulfure de diaryle, sels correspondant et agents immunosuppresseur utilisant ces derives
DE60235900D1 (de)	2001-09-27	2010-05-20	Kyorin Seiyaku Kk	Osuppressivum
ATE448193T1 (de)	2002-01-18	2009-11-15	Merck & Co Inc	ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
WO2003061567A2 (fr)	2002-01-18	2003-07-31	Merck & Co., Inc.	Antagonistes sélectifs du récepteur s1p1/edg1
CA2473740A1 (fr)	2002-01-18	2003-07-31	David Solow-Cordero	Procedes pour traiter des pathologies associees a un recepteur d'edg
JP4430941B2 (ja)	2002-01-18	2010-03-10	メルクエンドカムパニーインコーポレーテッド	Ｅｄｇ受容体作動薬
US7781617B2 (en) *	2004-07-16	2010-08-24	Kyorin Pharmaceutical Co., Ltd	Effective use method of medicaments and method of preventing expression of side effect

2004
- 2004-04-06 PE PE2012002027A patent/PE20130200A1/es not_active Application Discontinuation
- 2004-04-06 AR ARP040101162A patent/AR043987A1/es not_active Application Discontinuation
- 2004-04-06 PE PE2015000303A patent/PE20150676A1/es not_active Application Discontinuation
- 2004-04-06 ES ES04725895T patent/ES2320767T3/es not_active Expired - Lifetime
- 2004-04-06 GR GR20040100121A patent/GR1005052B/el unknown
- 2004-04-06 EP EP10184951.1A patent/EP2316431B1/fr not_active Revoked
- 2004-04-06 HR HRP20100601AA patent/HRP20100601B1/hr not_active IP Right Cessation
- 2004-04-06 PE PE2013000382A patent/PE20131352A1/es active IP Right Grant
- 2004-04-06 ES ES200400852A patent/ES2228282B1/es not_active Expired - Fee Related
- 2004-04-06 DK DK04725895T patent/DK1613288T3/da active
- 2004-04-06 PT PT04725895T patent/PT1613288E/pt unknown
- 2004-04-06 GB GB0407819A patent/GB2400318B/en not_active Expired - Lifetime
- 2004-04-06 NZ NZ586280A patent/NZ586280A/en not_active IP Right Cessation
- 2004-04-06 DK DK10184951.1T patent/DK2316431T3/en active
- 2004-04-06 DE DE201112100047 patent/DE122011100047I1/de active Pending
- 2004-04-06 PE PE2008001684A patent/PE20090743A1/es not_active Application Discontinuation
- 2004-04-06 DE DE102004016947A patent/DE102004016947A1/de not_active Ceased
- 2004-04-06 CA CA2521325A patent/CA2521325C/fr not_active Expired - Lifetime
- 2004-04-06 KR KR1020057019066A patent/KR20050121712A/ko not_active Ceased
- 2004-04-06 AT ATA606/2004A patent/AT501681B1/de not_active IP Right Cessation
- 2004-04-06 PE PE2004000355A patent/PE20050396A1/es not_active Application Discontinuation
- 2004-04-06 SI SI200432283T patent/SI2316431T1/sl unknown
- 2004-04-06 US US10/552,005 patent/US20060275357A1/en not_active Abandoned
- 2004-04-06 DE DE602004017847T patent/DE602004017847D1/de not_active Expired - Lifetime
- 2004-04-06 KR KR1020127019448A patent/KR101367574B1/ko not_active Expired - Lifetime
- 2004-04-06 PL PL04725895T patent/PL1613288T3/pl unknown
- 2004-04-06 FR FR0450692A patent/FR2854073B1/fr not_active Expired - Lifetime
- 2004-04-06 EP EP14163450.1A patent/EP2769713A1/fr not_active Withdrawn
- 2004-04-06 MX MXPA05010860A patent/MXPA05010860A/es active IP Right Grant
- 2004-04-06 AU AU2004228929A patent/AU2004228929B2/en not_active Expired
- 2004-04-06 NZ NZ542622A patent/NZ542622A/xx not_active IP Right Cessation
- 2004-04-06 EP EP08161161A patent/EP2008650A3/fr not_active Withdrawn
- 2004-04-06 WO PCT/EP2004/003656 patent/WO2004089341A1/fr not_active Ceased
- 2004-04-06 IT IT000682A patent/ITMI20040682A1/it unknown
- 2004-04-06 BR BRPI0409250A patent/BRPI0409250B8/pt active IP Right Grant
- 2004-04-06 HR HR20100600A patent/HRP20100600A2/hr not_active Application Discontinuation
- 2004-04-06 DE DE202004021680U patent/DE202004021680U1/de not_active Expired - Lifetime
- 2004-04-06 KR KR1020107029859A patent/KR20110005320A/ko not_active Ceased
- 2004-04-06 SI SI200431037T patent/SI1613288T1/sl unknown
- 2004-04-06 AT AT04725895T patent/ATE414508T1/de active
- 2004-04-06 ES ES10184951.1T patent/ES2556947T3/es not_active Expired - Lifetime
- 2004-04-06 CA CA2707750A patent/CA2707750A1/fr not_active Abandoned
- 2004-04-06 SG SG2008040545A patent/SG175449A1/en unknown
- 2004-04-06 PL PL10184951.1T patent/PL2316431T3/pl unknown
- 2004-04-06 HU HUE10184951A patent/HUE028247T2/en unknown
- 2004-04-06 CN CN2010101213007A patent/CN101797241B/zh not_active Expired - Lifetime
- 2004-04-06 JP JP2004111761A patent/JP5495467B2/ja not_active Expired - Lifetime
- 2004-04-06 EP EP10186307A patent/EP2319502A1/fr not_active Withdrawn
- 2004-04-06 EP EP04725895A patent/EP1613288B1/fr not_active Expired - Lifetime
- 2004-04-06 HR HR20050886A patent/HRP20050886B1/xx not_active IP Right Cessation
- 2004-04-06 CN CN2004800092370A patent/CN1767819B/zh not_active Expired - Lifetime
- 2004-04-06 RU RU2005134173/15A patent/RU2358716C2/ru not_active IP Right Cessation
- 2004-04-06 NZ NZ592339A patent/NZ592339A/xx not_active IP Right Cessation
- 2004-04-07 BE BE2004/0180A patent/BE1015972A5/fr not_active IP Right Cessation
- 2004-04-07 CL CL200400745A patent/CL2004000745A1/es unknown
- 2004-04-07 MY MYPI20041275A patent/MY141249A/en unknown
- 2004-04-07 TW TW093109631A patent/TWI332847B/zh active
2005
- 2005-09-14 ZA ZA200507394A patent/ZA200507394B/en unknown
- 2005-09-15 IL IL170888A patent/IL170888A/en active IP Right Grant
- 2005-10-07 TN TNP2005000256A patent/TNSN05256A1/en unknown
- 2005-10-07 EC EC2005006090A patent/ECSP056090A/es unknown
- 2005-10-19 MA MA28560A patent/MA27729A1/fr unknown
- 2005-11-01 IS IS8114A patent/IS2682B/is unknown
- 2005-11-07 NO NO20055231A patent/NO329332B1/no active Protection Beyond IP Right Term
2008
- 2008-05-08 AT AT0074408A patent/AT504853A2/de not_active Application Discontinuation
- 2008-08-11 US US12/189,323 patent/US8324283B2/en not_active Expired - Fee Related
- 2008-08-13 US US12/191,098 patent/US20090203798A1/en not_active Abandoned
2009
- 2009-02-17 RU RU2009105403/15A patent/RU2009105403A/ru not_active Application Discontinuation
- 2009-02-19 CY CY20091100192T patent/CY1110260T1/el unknown
- 2009-03-12 IL IL197578A patent/IL197578A/en active IP Right Grant
2010
- 2010-02-18 NO NO20100250A patent/NO334116B1/no unknown
- 2010-02-25 IS IS8885A patent/IS8885A/is unknown
- 2010-08-25 JP JP2010188835A patent/JP5543298B2/ja not_active Expired - Lifetime
- 2010-10-26 AR ARP100103931A patent/AR078782A2/es not_active Application Discontinuation
- 2010-10-26 AR ARP100103930A patent/AR078781A2/es not_active Application Discontinuation
- 2010-11-17 RU RU2010146697/15A patent/RU2475236C2/ru active
- 2010-11-18 RU RU2010147000/15A patent/RU2475237C2/ru active
2011
- 2011-01-10 US US12/987,726 patent/US20110105620A1/en not_active Abandoned
- 2011-03-01 CL CL2011000450A patent/CL2011000450A1/es unknown
- 2011-09-06 HU HUS1100016C patent/HUS1100016I1/hu unknown
- 2011-09-08 LU LU91867C patent/LU91867I2/fr unknown
- 2011-09-08 BE BE2011C030C patent/BE2011C030I2/fr unknown
- 2011-09-08 CY CY2011013C patent/CY2011013I2/el unknown
- 2011-09-08 NO NO2011016C patent/NO2011016I2/no unknown
- 2011-09-08 FR FR11C0036C patent/FR11C0036I2/fr active Active
2012
- 2012-11-15 RU RU2012148593/15A patent/RU2012148593A/ru not_active Application Discontinuation
- 2012-12-20 US US13/721,278 patent/US20130108675A1/en not_active Abandoned
2013
- 2013-04-23 JP JP2013090602A patent/JP2013177404A/ja active Pending
- 2013-09-16 US US14/027,943 patent/US20140011885A1/en not_active Abandoned
- 2013-09-26 NO NO20131287A patent/NO335120B1/no unknown
2014
- 2014-05-23 US US14/285,808 patent/US20140255497A1/en not_active Abandoned
2015
- 2015-10-12 IL IL242037A patent/IL242037A0/en unknown
- 2015-12-29 CY CY20151101194T patent/CY1117071T1/el unknown
2017
- 2017-06-27 US US15/634,579 patent/US20170290787A1/en not_active Abandoned
2019
- 2019-02-13 US US16/274,357 patent/US20190175527A1/en not_active Abandoned
2020
- 2020-04-03 US US16/839,703 patent/US20200237690A1/en not_active Abandoned
2021
- 2021-10-14 US US17/501,173 patent/US20220031609A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK2316431T3 (en)	2016-01-11
LU91867I9 (fr)	2019-01-03
US20200237690A1 (en)	2020-07-30
CA2707750A1 (fr)	2004-10-21
NO334116B1 (no)	2013-12-16
DE202004021680U1 (de)	2010-04-22
US8324283B2 (en)	2012-12-04
DE122011100047I1 (de)	2011-12-15
TNSN05256A1 (en)	2007-07-10
BRPI0409250B1 (pt)	2017-07-11
NO20131287L (no)	2006-01-09
US20220031609A1 (en)	2022-02-03
IL197578A0 (en)	2011-07-31
MY141249A (en)	2010-03-31
KR101367574B1 (ko)	2014-02-25
US20110105620A1 (en)	2011-05-05
DK1613288T3 (da)	2009-03-23
FR11C0036I2 (fr)	2023-12-29
HRP20050886B1 (en)	2011-01-31
GR20040100121A (el)	2004-12-17
JP5543298B2 (ja)	2014-07-09
US20140255497A1 (en)	2014-09-11
KR20050121712A (ko)	2005-12-27
ATE414508T1 (de)	2008-12-15
RU2475236C2 (ru)	2013-02-20
HK1155647A1 (en)	2012-05-25
RU2005134173A (ru)	2006-09-10
JP2004307506A (ja)	2004-11-04
NZ586280A (en)	2011-12-22
BE2011C030I2 (fr)	2023-03-07
DE102004016947A1 (de)	2004-10-21
EP2008650A3 (fr)	2011-04-27
EP2316431B1 (fr)	2015-09-30
AT501681A1 (de)	2006-10-15
NO20055231L (no)	2006-01-09
PL2316431T3 (pl)	2016-09-30
US20130108675A1 (en)	2013-05-02
JP2011006461A (ja)	2011-01-13
US20080311188A1 (en)	2008-12-18
NO2011016I2 (no)	2012-08-27
FR2854073A1 (fr)	2004-10-29
EP2319502A1 (fr)	2011-05-11
US20060275357A1 (en)	2006-12-07
PE20090743A1 (es)	2009-07-17
ZA200507394B (en)	2007-03-28
MA27729A1 (fr)	2006-01-02
CA2521325C (fr)	2010-09-14
RU2010146697A (ru)	2012-05-27
US20090203798A1 (en)	2009-08-13
HRP20100601A2 (hr)	2011-03-31
SG175449A1 (en)	2011-11-28
CY2011013I1 (el)	2014-04-09
WO2004089341A1 (fr)	2004-10-21
HRP20050886A2 (en)	2006-11-30
NO20100250L (no)	2006-01-09
JP2013177404A (ja)	2013-09-09
PL1613288T3 (pl)	2009-07-31
CN1767819A (zh)	2006-05-03
ES2228282B1 (es)	2006-02-16
NO335120B1 (no)	2014-09-22
KR20120101148A (ko)	2012-09-12
PE20050396A1 (es)	2005-07-05
HRP20100601B1 (hr)	2016-12-02
EP2316431A1 (fr)	2011-05-04
IL170888A (en)	2010-06-16
CY2011013I2 (el)	2014-04-09
NO329332B1 (no)	2010-09-27
EP2008650A2 (fr)	2008-12-31
CY1117071T1 (el)	2017-04-05
HUS1100016I1 (hu)	2016-08-29
RU2358716C2 (ru)	2009-06-20
GR1005052B (el)	2005-11-30
NO2011016I1 (no)	2011-09-19
AU2004228929B2 (en)	2008-02-07
BRPI0409250B8 (pt)	2022-01-18
AT504853A2 (de)	2008-08-15
AU2004228929A1 (en)	2004-10-21
RU2475237C2 (ru)	2013-02-20
BRPI0409250A (pt)	2006-03-28
AR078782A2 (es)	2011-11-30
AT501681B1 (de)	2012-04-15
US20140011885A1 (en)	2014-01-09
PE20131352A1 (es)	2013-11-14
BE1015972A5 (fr)	2005-12-06
CL2011000450A1 (es)	2011-11-25
AR078781A2 (es)	2011-11-30
EP1613288A1 (fr)	2006-01-11
HK1091114A1 (en)	2007-01-12
ES2320767T3 (es)	2009-05-28
CY1110260T1 (el)	2014-04-09
IL197578A (en)	2015-10-29
IS2682B (is)	2010-10-15
KR20110005320A (ko)	2011-01-17
ECSP056090A (es)	2006-03-01
EP1613288B1 (fr)	2008-11-19
RU2010147000A (ru)	2012-08-10
ITMI20040682A1 (it)	2004-07-06
RU2009105403A (ru)	2010-08-27
AR043987A1 (es)	2005-08-17
HUE028247T2 (en)	2016-12-28
IS8885A (is)	2010-02-25
US20190175527A1 (en)	2019-06-13
TW200503784A (en)	2005-02-01
CN101797241B (zh)	2013-03-27
FR2854073B1 (fr)	2008-03-14
DE602004017847D1 (de)	2009-01-02
IS8114A (is)	2005-11-01
IE20040246A1 (en)	2004-12-15
US20170290787A1 (en)	2017-10-12
JP5495467B2 (ja)	2014-05-21
FR11C0036I1 (fr)	2011-10-14
ES2228282A1 (es)	2005-04-01
PE20150676A1 (es)	2015-05-17
CN1767819B (zh)	2010-07-28
CN101797241A (zh)	2010-08-11
ES2556947T3 (es)	2016-01-21
MXPA05010860A (es)	2006-05-25
GB2400318B (en)	2005-08-10
CA2521325A1 (fr)	2004-10-21
GB2400318A (en)	2004-10-13
SI1613288T1 (sl)	2009-04-30
HK1071685A1 (en)	2005-07-29
PT1613288E (pt)	2009-02-25
SI2316431T1 (sl)	2016-04-29
NZ542622A (en)	2009-01-31
GB0407819D0 (en)	2004-05-12
TWI332847B (en)	2010-11-11
NO20055231D0 (no)	2005-11-07
CL2004000745A1 (es)	2005-02-11
NZ592339A (en)	2012-09-28
PE20130200A1 (es)	2013-03-09
EP2769713A1 (fr)	2014-08-27
HRP20100600A2 (hr)	2011-03-31
IL242037A0 (en)	2015-11-30
RU2012148593A (ru)	2014-05-20

Publication	Publication Date	Title
LU91867I2 (fr)	2011-11-08	Fingolimod et ses dérivés pharmaceutiquement acceptables (GILENYA®)
BR0306870A (pt)	2004-11-03	Composição farmacêutica oral, e, método para preparar a mesma
BR0206695A (pt)	2004-04-20	Formas de dosagem de epotilonas para administração oral
WO2004069198A3 (fr)	2004-10-07	Formes galeniques solides orales transmucosales exemptes de sucre et utilisations de celles-ci
WO2004032866A3 (fr)	2004-07-29	Preparations therapeutiques
WO2006025070A3 (fr)	2006-10-12	Nebivolol et ses sels pharmaceutiquement acceptables, procede de preparation et compositions pharmaceutiques de nebivolol
PY0323128A (es)	2012-12-03	Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas
DK1185253T3 (da)	2004-04-05	Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
DE602004005564D1 (de)	2007-05-10	Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten
ATE499939T1 (de)	2011-03-15	Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
AP2003002763A0 (en)	2003-03-31	Controlled release formulations for oral administration
EP1818049A3 (fr)	2008-11-19	Atorvastatin stabilisée
WO2010046933A3 (fr)	2010-07-01	Compositions pharmaceutiques de linézolid à goût masqué
WO2008060546A3 (fr)	2009-04-30	Formulations orales
WO2004012722A3 (fr)	2004-04-08	Preparation de bicifadine
NO20064808L (no)	2006-12-15	Orale matrixformuleringer med licarbazepin
WO2005051349A3 (fr)	2005-07-28	Compositions pharmaceutiques de mirtazapine
MY145885A (en)	2012-05-15	Controlled release formulations for oral administration
ECSP055749A (es)	2005-08-11	Formulacion de tramadol de liberacion sostenida con eficacia de 24 horas